This site is intended for healthcare professionals

Merck KGaA and Pfizer agree to terminate the JAVELIN Head and Neck 100 trial of Bavencio as unlikely to show a statistically significant improvement in progression-free survival.

Read time: 1 mins
Published:14th Mar 2020
Condition: Head & Neck Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest